Glenmark receives FDA approval for lidocaine ointment

The Food and Drug Administration recently approved India-based Glenmark Pharmaceutical’s lidocaine ointment.

Advertisement

The medication reduces itching and pain associated with skin conditions like scrapes, minor burns, bug bites and eczema.

Lidocaine is a generic version of Britain-based AstraZeneca’s Xylocaine ointment. Xylocaine reported annual sales of about $373 million for the 12-month period ending in July, according to data from IMS Health.

Glenmark’s U.S. portfolio includes 109 products. The company has 62 drug applications pending approval from the FDA.

More articles on supply chain:

5 myths about the EpiPen controversy
4 quotes from supply chain leaders on improving physician engagement
5 ways Mylan continues to dominate the epinephrine market

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply Chain

Advertisement

Comments are closed.